Anavasi grows executive team after funding rounds

By LabPulse.com staff writers

January 14, 2022 -- Anavasi Diagnostics recently made three additions to its executive team in the wake of the company completing a $6 million seed round and a $2.6 million founder's round.

New appointments include Scott Hales as chief financial officer, Guy Ellis as chief operating officer, and James McMenamy as chief commercial officer. The company is also preparing for an announcement in the first quarter of 2022 on a series A funding round.

Anavasi is preparing for filing of an emergency use authorization (EUA) for its AscencioDx platform, which detects the RNA characteristics of SARS-CoV-2. The U.S. National Institutes of Health (NIH) Rapid Acceleration of Diagnostics (RADx) initiative awarded the company $14.9 million in November to help launch and market the platform.

Anavasi secures $14.9M from NIH for SARS-CoV-2 assay
Anavasi Diagnostics has secured $14.9 million from the U.S. National Institutes of Health (NIH) to accelerate development of its AscencioDx assay...

Copyright © 2022 LabPulse.com

Last Updated ls 1/14/2022 10:26:27 AM



Subscribe Today
Do you want to be a Microbiology Insider?

When LabPulse gets hot new information, our Insiders are the first to find out. Stay current in today's competitive market by receiving our exclusive free email updates.

Yes, Keep Me Current